Evolvere BioSciences
Making Next-Generation Antibiotics that Outpace Bacterial Evolution
Founders
- Adam WinnifrithFounder/CEO
- Piotr JedryszekFounder/CTO
- Weronika SlesakFounder
Same space
Competitors
Closest in what they build, same category.
Adjacent
Overlapping tags, a different niche.
AlixiaW22Targeting the Tumor Ecosystem to address cancer drug resistance.Shared: biotech, therapeutics, biotechnologyActive
Sensible BiotechnologiesS21Unlocking the next generation of mRNA medicinesShared: biotech, therapeutics, biotechnologyActive
Paceline BioF25Accelerating clinical ops for biotech & pharmaShared: ai-powered drug discovery, biotech, biotechnologyActive
SFA TherapeuticsS21Regulating the immune system to block cancer & autoimmune diseasesShared: ai-powered drug discovery, biotech, biotechnologyActive
NanograbS23Deliver genes to any cell with AIShared: ai-powered drug discovery, biotech, therapeuticsActive
Also from S24 in AI
Batchmates in Summer 2024.
Ångström AIS24Gen AI molecular simulations that reproduce wetlab resultsActive
AminoAnalyticaS24The AI scientist for always-on biodefenseActive
AnthrogenS24We work on generalizable tools for the next era of biotech.Active
Baseline AIS24AI document creation and data management for clinical trialsInactive
Ligo BiosciencesS24Enzyme design models.Active
UndermindS24An AI agent for scientific researchActive
About Evolvere BioSciences
🦠🤖 We use our computational models to make next-generation antibiotics that outcompete bacterial evolution and precisely target pathogenic bacteria, without harming good microbes or human cells. ☠️ Current antibiotics stop working because bacteria evolve resistance to them. This makes drug-resistant bacteria a looming global health crisis - already killing more people than malaria and AIDS and it is getting exponentially worse 📈. 🧬 Our approach leverages co-evolutionary protein-protein interaction datasets combined with AI to forecast bacterial mutations and create ‘future-proof’ antibiotics, addressing antibiotic resistance before it develops. This changes the game for how frequently society will need to make new antibiotics and how long our new antibiotics will be able to treat patients 👩⚕️. We are a team of biochemists and evolutionary biologists who met at the University of Oxford.
Oxford, England, United Kingdom
Evolvere BioSciences: questions
Which YC batch was Evolvere BioSciences in?
Evolvere BioSciences was in Y Combinator's Summer 2024 batch (S24).
Is Evolvere BioSciences still active?
Y Combinator lists Evolvere BioSciences as active.
Who founded Evolvere BioSciences?
Evolvere BioSciences's founders, as listed on its YC page: Adam Winnifrith (Founder/CEO), Piotr Jedryszek (Founder/CTO), Weronika Slesak (Founder).
Where is Evolvere BioSciences based?
Evolvere BioSciences lists Oxford, England, United Kingdom as its location on YC's directory.
Not affiliated with Y Combinator. From YC's public directory. Logos via logo.dev; trademarks belong to their owners.